Drug intelligence / Profile preview

L2114

Development stage: Preclinical
Lead developer: iLeadBMS
Modality: Small Molecules
Administration: Oral

Overview

L2114 (also known as IL-2114) is an orally available small molecule inhibitor of ABL tyrosine kinase (ABL1) currently in discovery/preclinical development by iLeadBMS. The drug is being developed for the treatment of neurodegenerative disorders, specifically Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). By inhibiting ABL tyrosine kinase, L2114 aims to prevent neurodegeneration and promote cell survival, addressing key pathological pathways in these progressive neurological conditions.

Targets

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)

Beyond the preview

Go deeper on L2114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L2114.

Explore the full profile